Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report

Nivolumab, an antiprogrammed death-1 checkpoint inhibitor, has been approved for use in unresectable/metastatic renal cell carcinoma (RCC). Nivolumab-induced pneumonitis, a rare, but often severe and potentially life-threatening immune-related adverse event, has been reported, typically, early durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendiola, Vincent Louie, Kesireddy, Meghana, Jana, Bagi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944973/
https://www.ncbi.nlm.nih.gov/pubmed/31949965
http://dx.doi.org/10.1155/2019/6759472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944973/
https://www.ncbi.nlm.nih.gov/pubmed/31949965
http://dx.doi.org/10.1155/2019/6759472

Ejemplares similares